Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283440 | 1.00 | SLC6A2 (1.00) | SLC6A2ADRA2CSLC6A4SLC6A3ADRB2 | |
| SCHEMBL14595288 | 1.00 | SLC6A2 (1.00) | SLC6A2ADRA2CSLC6A4SLC6A3ADRB2 | |
| SCHEMBL6438236 | 1.00 | SLC6A2 (1.00) | SLC6A2ADRA2CSLC6A4SLC6A3ADRB2 | |
| Hydrochloric Acid SCHEMBL5042869 | 0.99 | SLC6A2 (1.00) | SLC6A2ADRA2CSLC6A4SLC6A3ADRB2 | |
| Hydrochloric Acid SCHEMBL5042868 | 0.99 | SLC6A2 (1.00) | SLC6A2ADRA2CSLC6A4SLC6A3ADRB2 | |
| Hydrochloric Acid SCHEMBL5042313 | 0.99 | SLC6A2 (1.00) | SLC6A2ADRA2CSLC6A4SLC6A3ADRB2 | |
| SCHEMBL14203022 | 0.91 | SLC6A2 (0.82) | SLC6A2ADRA2CSLC6A4SLC6A3HRH1 | |
| SCHEMBL5042389 | 0.91 | SLC6A2 (0.82) | SLC6A2ADRA2CSLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL5048069 | 0.90 | SLC6A2 (0.83) | SLC6A2ADRA2CSLC6A4SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL5042263 | 0.90 | SLC6A2 (0.83) | SLC6A2ADRA2CSLC6A4SLC6A3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354920-B2 | Aryl and heteroaryl morpholine derivatives | ELI LILLY AND COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| EP-1534694-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004018441-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A2 1/4885ADRA2C 45/4885SLC6A4 3/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885ADRA2C 48/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.